Application 218488
- Type
- ANDA
- Sponsor
- APOTEX
Application Products#
| Product | Drug | Ingredient | Form | Strength | Reference drug | Reference standard |
|---|---|---|---|---|---|---|
| 001 | EVEROLIMUS | EVEROLIMUS | TABLET;ORAL | 2.5MG | No | No |
| 002 | EVEROLIMUS | EVEROLIMUS | TABLET;ORAL | 5MG | No | No |
| 003 | EVEROLIMUS | EVEROLIMUS | TABLET;ORAL | 7.5MG | No | No |
| 004 | EVEROLIMUS | EVEROLIMUS | TABLET;ORAL | 10MG | No | No |
Orange Book products#
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| A218488-001 | EVEROLIMUS | EVEROLIMUS | 2.5MG | TABLET / ORAL | AB | 2026-05-12 | |
| A218488-002 | EVEROLIMUS | EVEROLIMUS | 5MG | TABLET / ORAL | AB | 2026-05-12 | |
| A218488-003 | EVEROLIMUS | EVEROLIMUS | 7.5MG | TABLET / ORAL | AB | 2026-05-12 | |
| A218488-004 | EVEROLIMUS | EVEROLIMUS | 10MG | TABLET / ORAL | AB | 2026-05-12 |
Therapeutic equivalence codes#
| Application-product | TE code |
|---|---|
| A218488-001 | AB |
| A218488-002 | AB |
| A218488-003 | AB |
| A218488-004 | AB |
Observed Orange Book product history#
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | A218488-001 | EVEROLIMUS | 2.5MG | TABLET / ORAL | AB | 2026-05-12 | a50c72e98297… | |
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | A218488-002 | EVEROLIMUS | 5MG | TABLET / ORAL | AB | 2026-05-12 | a50c72e98297… | |
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | A218488-003 | EVEROLIMUS | 7.5MG | TABLET / ORAL | AB | 2026-05-12 | a50c72e98297… | |
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | A218488-004 | EVEROLIMUS | 10MG | TABLET / ORAL | AB | 2026-05-12 | a50c72e98297… |
Observed Orange Book normalized TE history#
| Captured | Edition | Application-product | TE code | Order | Source SHA-256 |
|---|---|---|---|---|---|
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | A218488-001 | AB | 1 | a50c72e98297… |
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | A218488-002 | AB | 1 | a50c72e98297… |
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | A218488-003 | AB | 1 | a50c72e98297… |
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | A218488-004 | AB | 1 | a50c72e98297… |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Everolimus | EVEROLIMUS TABLETS | Breckenridge Pharmaceutical, Inc. | c7bb6ba1-9a7f-43f5-b058-ef26d4b59221 | 2026-07-06 | Boxed warning, Warnings, Adverse reactions | Everolimus |
| Everolimus | EVEROLIMUS | Biocon Pharma Inc. | 5b809dfe-c076-07c5-207e-178c3f0d32d3 | 2026-06-30 | Warnings, Adverse reactions | Everolimus EVEROLIMUS |
| Everolimus | EVEROLIMUS | Teva Pharmaceuticals USA, Inc. | e3bca36b-29ed-4a2b-a1be-a57b6af805f6 | 2026-06-29 | Warnings, Adverse reactions | Everolimus EVEROLIMUS |
| EVEROLIMUS | EVEROLIMUS | Amneal Pharmaceuticals NY LLC | 6f1ae129-c21e-4c25-84c1-a6757d9a7eb2 | 2026-06-16 | Warnings, Adverse reactions | EVEROLIMUS EVEROLIMUS |
| TORPENZ | EVEROLIMUS | Upsher-Smith Laboratories, LLC | 4c0075dd-a0a8-4dc4-be32-1be8383fbbdc | 2026-06-10 | Warnings, Adverse reactions | EVEROLIMUS |
| Afinitor | EVEROLIMUS | Novartis Pharmaceuticals Corporation | 2150f73a-179b-4afc-b8ce-67c85cc72f04 | 2026-06-01 | Warnings, Adverse reactions | EVEROLIMUS |
| Yulithira | EVEROLIMUS | CivicaScript, LLC | 5e325efa-8ae6-4dac-b59b-d7c74c73186c | 2026-03-31 | Warnings, Adverse reactions | EVEROLIMUS |
| everolimus | EVEROLIMUS | Novugen Pharma (USA) LLC. | 67e62e26-448d-46ec-b5a1-00dc1b5e26c6 | 2026-03-10 | Warnings, Adverse reactions | everolimus EVEROLIMUS |
| everolimus | EVEROLIMUS | Aurobindo Pharma Limited | 43ef3c29-0e25-4fdd-aea1-06a20af9bbab | 2026-02-26 | Boxed warning, Warnings, Adverse reactions | everolimus EVEROLIMUS |
| Zortress | EVEROLIMUS | Novartis Pharmaceuticals Corporation | e082a024-7850-400b-a5c2-2a140612562a | 2026-02-12 | Boxed warning, Warnings, Adverse reactions | EVEROLIMUS |
| Everolimus | EVEROLIMUS | Ascend Laboratories, LLC | 2693c497-a70b-4d00-b6db-602c872e5bed | 2025-12-19 | Boxed warning, Warnings, Adverse reactions | Everolimus EVEROLIMUS |
| Everolimus | EVEROLIMUS | Natco Pharma Limited | d44998bb-5deb-4ee7-a0a5-979fe3f49557 | 2025-10-14 | Boxed warning, Warnings, Adverse reactions | Everolimus EVEROLIMUS |
| Everolimus | EVEROLIMUS | Breckenridge Pharmaceutical, Inc. | 01f7b5fb-be0d-4adf-acd2-6899018de966 | 2025-09-05 | Warnings, Adverse reactions | Everolimus EVEROLIMUS |
| Everolimus | EVEROLIMUS | Biocon Pharma Inc. | 435da284-ef0e-ca90-e0db-bab9382922e0 | 2025-05-30 | Boxed warning, Warnings, Adverse reactions | Everolimus EVEROLIMUS |
| EVEROLIMUS | EVEROLIMUS | Biocon Pharma Inc. | 5fb55800-f322-6bb6-9dde-622925ef28bd | 2025-03-21 | Warnings, Adverse reactions | EVEROLIMUS EVEROLIMUS |
| Everolimus | EVEROLIMUS | Par Health USA, LLC | 59cb86d5-8706-4619-b074-af253d3e0b68 | 2025-01-13 | Boxed warning, Warnings, Adverse reactions | Everolimus EVEROLIMUS |
| Everolimus | EVEROLIMUS | Hikma Pharmaceuticals USA Inc. | cf2dd54b-7a1d-4401-9a01-75e68235e433 | 2024-09-03 | Boxed warning, Warnings, Adverse reactions | Everolimus EVEROLIMUS |
| EVEROLIMUS | EVEROLIMUS | NorthStar RxLLC | 5cfca904-b75c-5a39-8cb9-b99bb421bceb | 2024-08-02 | Warnings, Adverse reactions | EVEROLIMUS EVEROLIMUS |
| Everolimus | EVEROLIMUS | Hikma Pharmaceuticals USA Inc. | 5aaf2fb7-93f6-40d6-941a-9583a3794ce7 | 2024-04-23 | Warnings, Adverse reactions | Everolimus EVEROLIMUS |
| Everolimus | EVEROLIMUS | Natco Pharma Limited | e3dbbc24-7e55-4069-a305-e2cded2db641 | 2023-06-08 | Warnings, Adverse reactions | Everolimus EVEROLIMUS |